TY - JOUR
T1 - Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines
AU - de Souza, William M.
AU - Muraro, Stéfanie P.
AU - Souza, Gabriela F.
AU - Amorim, Mariene R.
AU - Sesti-Costa, Renata
AU - Mofatto, Luciana S.
AU - Forato, Julia
AU - Barbosa, Priscilla P.
AU - Toledo-Teixeira, Daniel A.
AU - Bispo-Dos-santos, Karina
AU - Parise, Pierina L.
AU - Brunetti, Natalia S.
AU - Moreira, Joselia C.O.
AU - Costa, Vitor A.
AU - Cardozo, Daniela M.
AU - Moretti, Maria L.
AU - Barros-Mazon, Silvia
AU - Marchesi, Gabriela F.
AU - Ambrosio, Christiane
AU - Spilki, Fernando R.
AU - Almeida, Valeria C.
AU - Vieira, Andre S.
AU - Zambon, Lair
AU - Farias, Alessandro S.
AU - Addas-Carvalho, Marcelo
AU - Benites, Bruno D.
AU - Marques, Rafael E.
AU - Sabino, Ester C.
AU - Von Zuben, Andrea B.
AU - Weaver, Scott C.
AU - Faria, Nuno R.
AU - Granja, Fabiana
AU - Angerami, Rodrigo N.
AU - Proença-Módena, José Luiz
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased trans-missibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8–3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.
AB - A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased trans-missibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8–3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.
KW - B.1.1.7
KW - COVID-19
KW - Outbreak
KW - SARS-CoV-2
KW - Vaccine
KW - Variant of concern
UR - http://www.scopus.com/inward/record.url?scp=85117940333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117940333&partnerID=8YFLogxK
U2 - 10.3390/v13112127
DO - 10.3390/v13112127
M3 - Article
AN - SCOPUS:85117940333
SN - 1999-4915
VL - 13
JO - Viruses
JF - Viruses
IS - 11
M1 - 2127
ER -